MedTrace Logo

Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis

NCT03256838 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2020-01-13

No results posted yet for this study

Summary

To assess the long-term safety and effectiveness of Nephoxil® for the treatment of hyperphosphatemia in patients with ESRD undergoing dialysis.

Conditions

  • Kidney Failure, Chronic
  • End-stage Renal Disease
  • Phosphorus Metabolism Disorders
  • Hyperphosphatemia

Interventions

DRUG

Ferric Citrate

Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.

Sponsors & Collaborators

  • Panion & BF Biotech Inc.

    lead INDUSTRY

Principal Investigators

  • Mai-Szu Wu, M.D. · Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-12
Primary Completion
2018-12-31
Completion
2019-05-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03256838 on ClinicalTrials.gov